US WorldMeds
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
US WorldMeds - overview
Location
Louisville, KY, US
Primary Industry
Pharmaceuticals
About
US WorldMeds, LLC is dedicated to developing and marketing innovative healthcare solutions, particularly focusing on unmet medical needs in the pharmaceutical sector. US WorldMeds specializes in the development and commercialization of healthcare products. The company is headquartered in Louisville, US. It was co-founded by Alessio Valentini and Breck Jones, who have previously been involved in various healthcare ventures.
The company has undergone strategic pivots, adapting its focus to address specific medical needs. US WorldMeds has implemented various funding rounds to support its growth and product development. US WorldMeds, LLC specializes in developing, licensing, and marketing innovative healthcare products aimed at addressing unmet medical needs. The company’s core product offerings include IWILFIN™ (eflornithine), an oral maintenance therapy for high-risk neuroblastoma, and LUCEMYRA™ (lofexidine), the first non-opioid medication for opioid withdrawal symptoms.
IWILFIN is designed for pediatric and adult patients who have shown a partial response to prior therapies, functioning to reduce the risk of relapse in high-risk neuroblastoma cases. LUCEMYRA provides relief from withdrawal symptoms for adults discontinuing opioid use, facilitating a smoother transition away from addiction. These products primarily target healthcare providers and institutions, including hospitals and outpatient clinics, in the United States, with plans for broader distribution in additional international markets. US WorldMeds generates revenue through the sale of its pharmaceutical products, marketed and distributed through various channels including partnerships with healthcare providers and direct sales to hospitals and pharmacies.
The company has established pricing structures based on the therapeutic value of its offerings, ensuring accessibility for end users through insurance coverage and patient assistance programs. Transactions typically occur on a B2B basis, with healthcare institutions purchasing these medications for distribution to patients, who are the ultimate end users. The revenue strategy focuses on maximizing patient access while fostering partnerships with healthcare systems and community health organizations to enhance overall patient outcomes.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals, Biomaterials
Website
www.usworldmeds.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.